Literature DB >> 30667474

Physicians' Perspectives on FDA Approval Standards and Off-label Drug Marketing.

Aaron S Kesselheim1, Steven Woloshin2, Zhigang Lu1, Frazer A Tessema1, Kathryn M Ross3, Lisa M Schwartz2.   

Abstract

Mesh：

Year:  2019        PMID： 30667474      PMCID： PMC6503563          DOI： 10.1001/jamainternmed.2018.8121

Source DB:  PubMed          Journal:  JAMA Intern Med        ISSN： 2168-6106            Impact factor:   21.873


× No keyword cloud information.
  5 in total

1.  Experts' Views on FDA Regulatory Standards for Drug and High-Risk Medical Devices: Implications for Patient Care.

Authors:  Sanket S Dhruva; Jonathan J Darrow; Aaron S Kesselheim; Rita F Redberg
Journal:  J Gen Intern Med       Date:  2022-02-09       Impact factor: 5.128

2.  Recommendations for Off-Label Drug Use in Ophthalmology in China: A Clinical Practice Guideline.

Authors:  Guangyao Li; Ningli Wang; Yu Zhang; Wenbin Wei; Hai Lu; Suodi Zhai; Chao Zhang
Journal:  Front Pharmacol       Date:  2022-05-24       Impact factor: 5.988

3.  Incorporating Patient Preferences via Bayesian Decision Analysis.

Authors:  Shomesh E Chaudhuri; Andrew W Lo
Journal:  Clin J Am Soc Nephrol       Date:  2021-03-03       Impact factor: 8.237

4.  Assessment of Knowledge, Attitude, and Practice of Obstetricians and Gynecologists Toward Off-Label Medicine Use in Female Reproductive Health Issues.

Authors:  Sadia Shakeel; Wajiha Iffat; Ambreen Qamar; Shagufta Nesar; Fareeha Butt; Sobia Naseem Siddiqui; Hina Rehman; Anees Ur Rehman
Journal:  Front Public Health       Date:  2022-03-24

5.  Patterns and Predictors of Off-Label Drug Prescribing in Psychiatric Practice: A Qualitative Study.

Authors:  Sadia Shakeel; Shagufta Nesar; Hina Rehman; Khizra Jamil; Imran Ahsan Mallick; Muhammad Shahid Mustafa; Mudassir Anwar; Shazia Jamshed
Journal:  Pharmacy (Basel)       Date:  2021-12-20
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.